Best Online Consultation with Oncologist doctors in Barcelona: TOP 9 doctors

Dr. Francesc Cobo Valien graduated from the Faculty of Medicine of the University of Barcelona in 1990.

He received his specialization in oncohematology at the Hospital Clínic de Barcelona in 1995. He combined medical practice and research activities in the period 1996-2002.

He received his Doctor of Medicine degree from the University of Barcelona in 2002.

Dr. Kobo continues his research and has been awarded grants:

•Interdepartmental Commission for Innovation of the Generalitat de Catalunya

•Scholarship Fund Universitaria Agustí Pedro i Pons

•Farreras Valentí & Schering Plough School of Hematology Scholarship

•Award for the best report at the Council of the Spanish Hematology Association

•Grant from the Catalan Society of Hematology

Specialization:

•Lymphoma

•Acute leukemia

•Chronic leukemia

•Autoimmune pancytopenia

Dr. Balaña received her medical degree from the Central University of Barcelona and completed her residency in medical oncology at one of the best public hospitals in Spain, Vall d'Hebrón Hospital.

She was a leading specialist in the treatment of brain tumors at the Institute of Oncology of Catalonia, a founding member and current president of the Spanish Neuro oncology Research Group (GEINO), and a member of the scientific committee of the European Association for Neuro-Oncology.

He is the recipient of prestigious research grants in the field of brain tumors.

Dr. Balaña is also a member of the European Society of Medical Oncology and the author of modern European protocols for the treatment of brain tumors, as well as the protocols of the Spanish Society of Medical Oncology (SEOM).

Dr. Balaña has published over 400 articles, books and scientific papers at national and international conferences.

He is the author of articles in prestigious scientific publications such as:

Lancet Oncology;

Nature Reviews in Clinical Oncology;

Clinical Cancer Research and others.

The doctor is an oncological surgeon specializing in peritoneal carcinomatosis and is part of the Teknon Oncology Institute’s Carcinomatosis Surgical Group since 2019. She completed her specialization at the Washington Hospital Center under Prof. Paul Sugarbaker and holds American Board of Surgery certification.

She is a member of several prestigious societies, including the American College of Surgeons and the Society of Surgical Oncology. Her academic roles have included Research Director at Inova Fairfax Hospital and Associate Professor positions at Virginia Commonwealth University and Georgetown University.

The doctor is responsible for thoracic malignancy management and oversees thoracic cancer trials at the Oncology Department. Their research focuses on optimizing chemotherapy in early-stage disease, evaluating new therapies, exploring pharmacogenomic approaches, integrating immunotherapy for lung cancer, and investigating resistance mechanisms to tyrosine-kinase inhibitors.

Holding a medical degree and a PhD in medical oncology from UAB, the doctor is a member of several prestigious oncology societies, including ESMO, ASCO, and IASLC. They have published numerous peer-reviewed articles and book chapters on thoracic malignancies and have held teaching positions at UAB and UVicc-UCC.

The doctor has focused research on paraneoplastic neurological syndromes, leading a panel that established diagnostic criteria. His work confirmed the immune hypothesis linking tumors to autoimmune neurological dysfunctions, with antibodies identified by him now essential for diagnosis.

Clinically, the doctor specializes in diagnosing and managing gliomas, primary brain lymphomas, and cancer treatment-related neurotoxicities. Recent interests include neurological complications from immune checkpoint inhibitors and hematopoietic stem cell transplantation.

He holds an MD and PhD from Universitat Autónoma de Barcelona, completed a neurology residency in Barcelona, and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center.

The doctor specializes in angiogenesis, DNA repair mechanisms, and immunology, serving as Principal Investigator in clinical trials for ovarian, cervical, and endometrial cancer. With a degree in Medicine and Surgery from the Complutense University of Madrid and a PhD from Universidad Autonoma de Barcelona, the doctor has published over 100 works and presentations. The doctor is a Co-Chair of the GEICO Group and a faculty member for the Gyn-Track in the European Society of Medical Oncology. Additionally, the doctor is an active member of ASCO, ESMO, and SEOM.

The doctor specializes in lymphomas and chronic lymphocytic leukemia, leading innovations in the analysis and treatment of hematological diseases. Renowned globally for expertise in Chronic Lymphocytic Leukemia (CLL), the doctor conducts significant clinical and basic research, focusing on molecular pathogenesis and new therapeutic approaches.

Currently involved in over 80 studies from phase 1 to phase 3, the doctor contributes to the development of new drugs and treatments. As Head of Hematology at the IOB Institute of Oncology and Head of the Haematology Department at Vall d’Hebron University Hospital, the doctor has published over 100 articles in prestigious journals.

The doctor specializes in breast cancer and endocrine treatment, focusing on overcoming resistance to hormone therapy during adjuvant and metastatic disease. Actively involved in phase 1, 2, and 3 studies for breast cancer and melanoma, the doctor has contributed to the approval of new drugs, including cdk4/6 inhibitors like palbociclib and ribociclib for metastatic breast cancer, and immunotherapy treatments such as Pembrolizumab, Nivolumab, and Ipilimumab for melanoma. The doctor is a member of the Breast Cancer Unit and Melanoma Unit at Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology.

The doctor is a clinical scientist with expertise in the clinical application of laboratory findings in breast cancer, focusing on gene expression and molecular subtypes. The doctor designs and leads clinical trials for novel drugs and approaches at SOLTI, a Spanish breast cancer cooperative group.

Graduating with an MD from the University of Barcelona in 2003, the doctor completed a medical oncology fellowship at Vall d'Hebron Institute of Oncology and postdoctoral research at the University of North Carolina.

Currently, the doctor heads the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at IDIBAPS and is the President of SOLTI's Board of Directors. The doctor has co-founded Reveal Genomics and holds three patents.

With over 160 publications and an H-Index of 51, the doctor has been cited 13,479 times and has presented 95 communications internationally.